CN102056944A - 抗炎症药剂 - Google Patents

抗炎症药剂 Download PDF

Info

Publication number
CN102056944A
CN102056944A CN2009801210911A CN200980121091A CN102056944A CN 102056944 A CN102056944 A CN 102056944A CN 2009801210911 A CN2009801210911 A CN 2009801210911A CN 200980121091 A CN200980121091 A CN 200980121091A CN 102056944 A CN102056944 A CN 102056944A
Authority
CN
China
Prior art keywords
seq
human
deiminated
histone
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801210911A
Other languages
English (en)
Chinese (zh)
Inventor
约瑟夫·玛利亚·亨德里克·拉茨
雷纳多·杰勒杜斯·希尔瓦诺·齐尔里维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Modiquest BV
Original Assignee
Modiquest BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modiquest BV filed Critical Modiquest BV
Publication of CN102056944A publication Critical patent/CN102056944A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
CN2009801210911A 2008-06-04 2009-06-04 抗炎症药剂 Pending CN102056944A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP08157547.4 2008-06-04
EP08157547 2008-06-04
EP08171920.5 2008-12-17
EP08171920 2008-12-17
EP09155484 2009-03-18
EP09155484.0 2009-03-18
PCT/EP2009/056862 WO2009147201A2 (en) 2008-06-04 2009-06-04 Anti-inflammatory agents

Publications (1)

Publication Number Publication Date
CN102056944A true CN102056944A (zh) 2011-05-11

Family

ID=40943595

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801210911A Pending CN102056944A (zh) 2008-06-04 2009-06-04 抗炎症药剂

Country Status (16)

Country Link
US (2) US9718877B2 (https=)
EP (1) EP2294086B1 (https=)
JP (1) JP5528436B2 (https=)
KR (1) KR101752499B1 (https=)
CN (1) CN102056944A (https=)
AU (1) AU2009253923B2 (https=)
BR (1) BRPI0913945A2 (https=)
CA (1) CA2726511C (https=)
DK (1) DK2294086T3 (https=)
EA (1) EA023302B9 (https=)
ES (1) ES2652127T3 (https=)
IL (1) IL209741A0 (https=)
NO (1) NO2294086T3 (https=)
PL (1) PL2294086T3 (https=)
WO (1) WO2009147201A2 (https=)
ZA (1) ZA201008727B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459198A (zh) * 2014-05-05 2017-02-22 诺维奥斯玛特 类风湿性关节炎的血清学诊断方法
CN111741763A (zh) * 2017-12-29 2020-10-02 遗传工程与生物技术中心 包含apl型肽的药用组合物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2294086T3 (https=) 2008-06-04 2018-02-10
EP2332987A1 (en) 2009-12-10 2011-06-15 ModiQuest B.V. Anti-inflammatory agents directed against citrullinated epitopes
US20110262505A1 (en) 2010-04-22 2011-10-27 Gina Athwal Seaweed-derived cosmetic compositions
EP2402368A1 (en) 2010-07-02 2012-01-04 Toscana Biomarkers S.r.l. Histone citrullinated peptides and uses thereof
EP2527841A1 (en) * 2011-05-25 2012-11-28 Toscana Biomarkers S.r.l. Methods for the diagnosis of rheumatoid arthritis
WO2013105721A1 (ko) * 2012-01-13 2013-07-18 가톨릭대학교 산학협력단 류마티스 관절염 진단 키트
US9347941B2 (en) 2012-01-13 2016-05-24 Catholic University Industry-Academic Cooperation Foundation Diagnosis kit for rheumatoid arthritis
WO2013109185A1 (en) * 2012-01-19 2013-07-25 Vilara Ab Novel antibodies
FR3007411B1 (fr) * 2013-06-21 2015-07-03 Agronomique Inst Nat Rech Anticorps monocatenaire a chaine lourde de camelide dirige contre la chromatine et utilisations
US20160159922A1 (en) * 2013-07-24 2016-06-09 Vilara Ab Novel Antibodies for the Diagnosis and Treatment of Rheumatoid Arthritis
JP7037940B2 (ja) 2014-12-11 2022-03-17 シトリル べー．フェー． 特発性肺線維症の治療方法
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
CA2984380A1 (en) * 2015-05-05 2016-11-10 The Regents Of The University Of California H3.3 ctl peptides and uses thereof
EP3713966A1 (en) 2017-11-22 2020-09-30 Vacara AB Antibodies to citrullinated proteins
CA3102360A1 (en) * 2018-06-20 2019-12-26 Pharma Foods International Co., Ltd. Novel anti-pad2 antibody
EP3841120B1 (en) * 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4
KR20240005856A (ko) 2021-05-04 2024-01-12 씨트릴 비.브이. 세포 외 트랩 억제
EP4085973A1 (en) 2021-05-04 2022-11-09 Citryll B.V. Inhibition of eosinophil extracellular traps
EP4442705A1 (en) 2023-04-03 2024-10-09 Citryll B.V. Dosage
GB202318703D0 (en) 2023-12-07 2024-01-24 Citryll B V Diagnostic agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
NL1004539C2 (nl) 1996-11-15 1998-05-20 Stichting Tech Wetenschapp Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen.
EP1034186A2 (en) * 1997-11-28 2000-09-13 Innogenetics N.V. Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
CA2391356A1 (en) 1999-12-21 2001-06-28 Innogenetics N.V. Peptides designed for the diagnosis and treatment of rheumatoid arthritis
JP2007524583A (ja) 2003-03-07 2007-08-30 ロンドン・ヘルス・サイエンシズ・センター・リサーチ・インコーポレーテッド 自己免疫異常に関わるｈｌａ−ｄｒｍｈｃクラスｉｉ分子に関するペプチド
GB0721605D0 (en) 2007-11-02 2007-12-12 Cancer Rec Tech Ltd Prostrate cancer susceptibility screening
NO2294086T3 (https=) 2008-06-04 2018-02-10

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KLARESKOG LARS ET AL: "Immunity to citrullinated proteins in rheumatoid arthritis", 《ANNUAL REVIEW OF IMMUNOLOGY》 *
O"DELL JAMES R: "Therapeutic strategies for rheumatoid arthritis", 《NEW ENGLAND JOURNAL OF MEDICINE》 *
RAATS JOS MH ET AL: "Recombinant human monoclonal autoantibodies specific for citrulline-containing peptides from phage display libraries derived from patients with rheumatoid arthritis", 《JOURNAL OF RHEUMATOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459198A (zh) * 2014-05-05 2017-02-22 诺维奥斯玛特 类风湿性关节炎的血清学诊断方法
CN111741763A (zh) * 2017-12-29 2020-10-02 遗传工程与生物技术中心 包含apl型肽的药用组合物

Also Published As

Publication number Publication date
ZA201008727B (en) 2012-01-25
US9718877B2 (en) 2017-08-01
AU2009253923A1 (en) 2009-12-10
CA2726511C (en) 2018-07-10
BRPI0913945A2 (pt) 2016-09-27
EP2294086A2 (en) 2011-03-16
EA023302B1 (ru) 2016-05-31
PL2294086T3 (pl) 2018-02-28
CA2726511A1 (en) 2009-12-10
NO2294086T3 (https=) 2018-02-10
EA023302B9 (ru) 2016-10-31
EP2294086B1 (en) 2017-09-13
JP5528436B2 (ja) 2014-06-25
ES2652127T3 (es) 2018-01-31
WO2009147201A3 (en) 2010-01-28
US10703822B2 (en) 2020-07-07
KR101752499B1 (ko) 2017-06-29
US20110243945A1 (en) 2011-10-06
JP2011523555A (ja) 2011-08-18
KR20110015035A (ko) 2011-02-14
DK2294086T3 (en) 2018-01-02
AU2009253923B2 (en) 2014-02-13
IL209741A0 (en) 2011-02-28
EA201001865A1 (ru) 2011-06-30
WO2009147201A2 (en) 2009-12-10
US20170298146A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
US10703822B2 (en) Anti-inflammatory agents
EP2509999B1 (en) Anti-inflammatory agents directed against citrullinated epitopes
JP7835788B2 (ja) シトルリン化されたヒストン２ａ及び／又は４に結合する抗体
Chirivi et al. Anti-citrullinated protein antibodies as novel therapeutic drugs in rheumatoid arthritis
HK1156050A (en) Anti-inflammatory agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1156050

Country of ref document: HK

C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Holland

Applicant after: Modiquest B. V.

Address before: Nijmegen

Applicant before: Modiquest B. V.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110511

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1156050

Country of ref document: HK